Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 4
1996 1
1998 2
1999 3
2000 1
2001 1
2002 1
2003 5
2004 4
2005 6
2006 7
2007 12
2008 18
2009 24
2010 23
2011 26
2012 32
2013 34
2014 30
2015 35
2016 41
2017 52
2018 59
2019 45
2020 47
Text availability
Article attribute
Article type
Publication date

Search Results

466 results
Results by year
Filters applied: . Clear all
Page 1
Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition.
Avila-Carrasco L, Majano P, Sánchez-Toméro JA, Selgas R, López-Cabrera M, Aguilera A, González Mateo G. Avila-Carrasco L, et al. Front Pharmacol. 2019 Jul 30;10:715. doi: 10.3389/fphar.2019.00715. eCollection 2019. Front Pharmacol. 2019. PMID: 31417401 Free PMC article. Review.
Salvianolic acid-A and plumbagin block oxidative stress, while honokiol, gallic acid, piperlongumine, brusatol and paeoniflorin inhibit EMT transcription factors such as SNAIL, TWIST and ZEB. ...Overall, this opens up new therapeutic alternatives in cancer, infla
Salvianolic acid-A and plumbagin block oxidative stress, while honokiol, gallic acid, piperlongumine, brusatol and paeoniflorin inhib …
Safety and Toxicology of Magnolol and Honokiol.
Sarrica A, Kirika N, Romeo M, Salmona M, Diomede L. Sarrica A, et al. Planta Med. 2018 Nov;84(16):1151-1164. doi: 10.1055/a-0642-1966. Epub 2018 Jun 20. Planta Med. 2018. PMID: 29925102 Review.
Magnolia officinalis and Magnolia obovata bark extracts have been used for thousands of years in Chinese and Japanese traditional medicines and are still widely employed as herbal preparations for their sedative, antioxidant, anti-inflammatory, antibiotic, and antis …
Magnolia officinalis and Magnolia obovata bark extracts have been used for thousands of years in Chinese and Japanese traditional medicines …
Designing a broad-spectrum integrative approach for cancer prevention and treatment.
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Block KI, et al. Semin Cancer Biol. 2015 Dec;35 Suppl(Suppl):S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Semin Cancer Biol. 2015. PMID: 26590477 Free PMC article. Review.
Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. ...Using cancer hallmark phenotypes and the tumor microenvironment to account for the …
Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, s …
Honokiol: An anticancer lignan.
Rauf A, Patel S, Imran M, Maalik A, Arshad MU, Saeed F, Mabkhot YN, Al-Showiman SS, Ahmad N, Elsharkawy E. Rauf A, et al. Biomed Pharmacother. 2018 Nov;107:555-562. doi: 10.1016/j.biopha.2018.08.054. Epub 2018 Aug 13. Biomed Pharmacother. 2018. PMID: 30114639 Review.
Honokiol has inhibitory role on the proliferation, invasion and survival of cancer cells in in vitro as well as in vivo studies. ...The derivatization of honokiol results in compounds with interesting attributes in terms of cancer control. This review
Honokiol has inhibitory role on the proliferation, invasion and survival of cancer cells in in vitro as well as in vivo studie
Honokiol is a FOXM1 antagonist.
Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL, Gartel AL. Halasi M, et al. Cell Death Dis. 2018 Jan 24;9(2):84. doi: 10.1038/s41419-017-0156-7. Cell Death Dis. 2018. PMID: 29367668 Free PMC article.
More importantly, we found that honokiol's inhibitory effect on FOXM1 is a result of binding of honokiol to FOXM1. This binding is specific to honokiol, a dimerized allylphenol, and was not observed in compounds that either were monomeric allylphenols …
More importantly, we found that honokiol's inhibitory effect on FOXM1 is a result of binding of honokiol to FOXM1. This …
Controlling the master-upstream regulation of the tumor suppressor LKB1.
Kullmann L, Krahn MP. Kullmann L, et al. Oncogene. 2018 Jun;37(23):3045-3057. doi: 10.1038/s41388-018-0145-z. Epub 2018 Mar 15. Oncogene. 2018. PMID: 29540834 Review.
Moreover, mutations and misregulation of LKB1 have been reported to occur in most types of tumors and are among the most common aberrations in lung cancer. ...In particular the activation of AMPK upon energetic stress has been intensively analyzed in various diseases, incl …
Moreover, mutations and misregulation of LKB1 have been reported to occur in most types of tumors and are among the most common aberrations …
Bioactive Compounds: Multi-Targeting Silver Bullets for Preventing and Treating Breast Cancer.
Muniraj N, Siddharth S, Sharma D. Muniraj N, et al. Cancers (Basel). 2019 Oct 15;11(10):1563. doi: 10.3390/cancers11101563. Cancers (Basel). 2019. PMID: 31618928 Free PMC article. Review.
Cancer cells outsmart normal cells and evade apoptosis and it is one of the major hallmarks of cancer. The cardinal quest for anti-cancer drug discovery (bioactive or synthetic compounds) is to be able to re-induce the so called "programmed cell death" in
Cancer cells outsmart normal cells and evade apoptosis and it is one of the major hallmarks of cancer. The cardinal quest for
Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3.
Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP, Gius D, Gupta MP. Pillai VB, et al. Nat Commun. 2015 Apr 14;6:6656. doi: 10.1038/ncomms7656. Nat Commun. 2015. PMID: 25871545 Free PMC article.
Honokiol (HKL) is a natural biphenolic compound derived from the bark of magnolia trees with anti-inflammatory, anti-oxidative, anti-tumour and neuroprotective properties. ...
Honokiol (HKL) is a natural biphenolic compound derived from the bark of magnolia trees with anti-inflammatory, anti-oxidative
Antidepressant-Like Effect and Mechanism of Action of Honokiol on the Mouse Lipopolysaccharide (LPS) Depression Model.
Zhang B, Wang PP, Hu KL, Li LN, Yu X, Lu Y, Chang HS. Zhang B, et al. Molecules. 2019 May 28;24(11):2035. doi: 10.3390/molecules24112035. Molecules. 2019. PMID: 31141940 Free PMC article.
Moreover, honokiol ameliorated LPS-induced NF-κB activation in the hippocampus and significantly reduced the levels of the pro-inflammatory cytokines; tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), and interferon γ (IFN-γ). ...In summary, our results indic …
Moreover, honokiol ameliorated LPS-induced NF-κB activation in the hippocampus and significantly reduced the levels of the pro-inf
Targeting oncogenic transcription factors by polyphenols: A novel approach for cancer therapy.
Rajagopal C, Lankadasari MB, Aranjani JM, Harikumar KB. Rajagopal C, et al. Pharmacol Res. 2018 Apr;130:273-291. doi: 10.1016/j.phrs.2017.12.034. Epub 2018 Jan 4. Pharmacol Res. 2018. PMID: 29305909 Review.
Inflammation is one of the major causative factor of cancer and chronic inflammation is involved in all the major steps of cancer initiation, progression metastasis and drug resistance. ...Further combination of these natural products along with currently approved …
Inflammation is one of the major causative factor of cancer and chronic inflammation is involved in all the major steps of cancer
466 results
Jump to page
Feedback